Leadership & Pay ·
Pharming CEO Fabrice Chouraqui steps down; CCO Leverne Marsh and CFO Kenneth Lynard named interim co-CEOs
PHARPharming Group N.V.
Pharming Group N.V. announced on September 29, 2026, that CEO Fabrice Chouraqui has stepped down with immediate effect following a mutual agreement due to misalignment on strategic priorities. The Board appointed Chief Commercial Officer Leverne Marsh and Chief Financial Officer Kenneth Lynard as Interim Co-CEOs to ensure leadership continuity while a formal search for a permanent successor begins. Marsh will lead patient-focused operations, while Lynard oversees global corporate functions. The company affirmed that its strategy, pipeline, and commitment to patients remain unchanged. Pharming Group N.V. is a global biotechnology company focused on developing and commercializing innovative medicines for rare immune and genetic diseases.